Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4663657 | 0.90 | TRPA1 (0.36) | OPRM1OPRK1OPRD1ARRB1 | |
| SCHEMBL4663384 | 0.83 | OPRM1 (0.33) | ALDH1A1OPRM1OPRK1OPRD1SMN1; SMN2 | |
| SCHEMBL4665387 | 0.82 | SLC6A4 (0.44) | OPRM1OPRK1OPRD1 | |
| SCHEMBL4663731 | 0.80 | OPRM1 (0.36) | ALDH1A1OPRM1OPRK1OPRD1SMN1; SMN2 | |
| SCHEMBL4664046 | 0.80 | SMN1; SMN2 (0.48) | ALDH1A1OPRM1OPRK1OPRD1SMN1; SMN2 | |
| SCHEMBL4663541 | 0.77 | ALDH1A1 (0.39) | ALDH1A1OPRM1OPRK1OPRD1SMN1; SMN2 | |
| SCHEMBL4665352 | 0.76 | OPRM1 (0.35) | ALDH1A1OPRM1OPRK1OPRD1SMN1; SMN2 | |
| SCHEMBL4665379 | 0.76 | OPRK1 (0.42) | ALDH1A1OPRM1OPRK1OPRD1SMN1; SMN2 | |
| SCHEMBL4665434 | 0.76 | GMNN (0.39) | OPRM1OPRK1OPRD1DRD4 | |
| SCHEMBL4663618 | 0.76 | GMNN (0.39) | OPRM1OPRK1OPRD1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1571140-B1 | C-substituted cyclohexylmethylamine derivatives | GRUENENTHAL GMBH (DE) | 2008-11-12 | — | — | EP | claimed |
| US-7273952-B2 | Substituted C-cyclohexylmethylamine derivatives | GRUENENTHAL GMBH (DE) | 2007-09-25 | — | — | US | claimed |
| US-20030232891-A1 | Substituted C-cyclohexylmethylamine derivatives | GRUENENTHAL GMBH (DE) | 2003-12-18 | — | — | US | claimed |
| EP-1571140-B1 | C-substituted cyclohexylmethylamine derivatives | GRUENENTHAL GMBH (DE) | 2008-11-12 | — | — | EP | disclosed |
| US-7273952-B2 | Substituted C-cyclohexylmethylamine derivatives | GRUENENTHAL GMBH (DE) | 2007-09-25 | — | — | US | disclosed |
| EP-1368299-B1 | SUBSTITUTED C-CYCLOHEXYLMETHYLAMINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2006-07-26 | — | — | EP | disclosed |
| EP-1571140-A1 | C-substituted cyclohexylmethylamine derivatives | Grünenthal GmbH (DE) | 2005-09-07 | — | — | EP | disclosed |
| US-20030232891-A1 | Substituted C-cyclohexylmethylamine derivatives | GRUENENTHAL GMBH (DE) | 2003-12-18 | — | — | US | disclosed |
| EP-1368299-A2 | SUBSTITUTED C-CYCLOHEXYLMETHYLAMINE DERIVATIVES | Grünenthal GmbH (DE) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002030870-A2 | SUBSTITUTED C-CYCLOHEXYLMETHYLAMINE DERIVATIVES | Grünenthal GmbH (DE) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232891-A1 | Substituted C-cyclohexylmethylamine derivatives | CNR2, CNR1, HNMT | ALDH1A1 2922/4885OPRM1 5/4885OPRK1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.